Michael Pfreundschuh und B-Cell - Info zur Person

(1 - 11 von 11

)

Michael Pfreundschuh, MD | Authors - Cancer Networkwww.cancernetwork.com › authors › michael-pfreu...

www.cancernetwork.com

The Best Treatment for Diffuse Large B-Cell Lymphoma: A German Perspective · Rudolf Schmits, MD · Norbert Schmitz, MD · Michael Pfreundschuh, MD.

Diffuse large B-cell lymphoma - classic and novel prognostic factors ...library.ehaweb.org › eha › michael.pfreundschuh.di...

library.ehaweb.org

EHA Library. Pfreundschuh M ; Topic: 3Ab Diffuse large B-cell lymphoma. Prof. Dr. Michael Pfreundschuh Contributions · DOWNLOAD PUBLICATION.

The Biology of Tumorsbooks.google.ca › books

books.google.ca

15 IDENTIFICATION OF HUMAN TUMOR ANTIGENS USING THE B-CELL REPERTOIRE Michael Pfreundschuh, Özlem Türeci, and Ugur Sahin Medizinische Klinik I Saarland ...

New drugs for aggressive B-cell and T-cell lymphomas - ProQuest

www.proquest.com

Niels Murawski, Michael Pfreundschuh. Over the past decade an unprecedented number of new drugs for lymphomas have been developed. Most of these new.

Dose-intensified treatment of diffuse large B-cell lymphomas -...

www.sciencedirect.com

Carsten Zwick, Gerhard Held, Michael Pfreundschuh *, for the German High-Grade. Non-Hodgkin-Lymphoma Study Group. Innere Medizin I, Saarland University ...

Dose-Intensified Treatment of Advanced-Stage Diffuse Large B-Cell...

www.sciencedirect.com

Affiliations. Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany. ,. Michael Pfreundschuh. x. Michael Pfreundschuh. Search for articles ...

Treatment of diffuse large B-cell lymphomas | SpringerLink

link.springer.com

Aggressivenon-Hodgkin'slymphoma chemotherapy immunotherapy clinical trials monoclonal antibody. Michael Pfreundschuh: M.D. for the German High-Grade ...

Michael Pfreundschuh's Research on Prednisone (Sone) | CureHunter

www.curehunter.com

: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label